The Weekly Roundup: December 19-23

HCVAD Chemotherapy Treatment Regimen Shows Promise for Blastic Plasmacytoid Dendritic Cell Neoplasm

A retrospective study published in the journal Blood Advances found that hyperfractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone chemotherapy treatment (HCVAD) had higher rates of complete remission (CR) compared with other therapy regimens.

SNDA Submitted for Roflumilast Cream for the Treatment of Plaque Psoriasis Down to 2 Years

Arcutis Biotherapeutics' indication expansion is based on data from MUSE studies.

Case Study Shows Liposomal Daunorubicin and Cytarabine (Vyxeos) as Promising Treatment for BPDCN

The study published in the Journal of Investigative Medicine High Impact Case Reports found that treatment resulted in complete bone marrow response in refractory BPDCN.

Frontline Forum Part 1: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

In part 1 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

Phase 2 Clinical Trial of Synthetic Hypericin Underway for Treatment of Mild-to-Moderate Psoriasis

Patient enrollment is now open for the study conducted by late-stage biopharmaceutical company, Soligenix.

A Conversation About JAK Inhibitors in Atopic Dermatitis

In this DermView series recap, Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, review the changing landscape of atopic dermatitis treatment options and what is on the horizon.

Treatment of Plaque Psoriasis in Children

A variety of topicals and biologics are now available to treat children affected by this challenging condition.

Frontline Forum Part 2: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

In part 2 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

Studies Find High Prevalence of Suicidal Ideation in Patients with Vitiligo

Because vitiligo affects appearance, people with vitiligo are disproportionately affected by psychiatric conditions, including depression.

Helping Patients with Traction Alopecia: Basics, Treatment, and Prevention

Understanding traction alopecia (TA) is essential to helping patients prevent hair loss and repair damage.

Frontline Forum Part 3: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

In part 3 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

POLL: Which 2022 Psoriasis FDA Approval Were You Most Excited About?

Click here to answer this week's poll.

Was It Marketing or Was It Misrepresentation?

This month's Legal Eagle column explores a scenario of marketing vs. misrepresentation.

Frontline Forum Part 4: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

In part 4 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

Non-Invasive Test That May Help Predict Eczema in Babies

Results from the test reveal that high levels of the immune biomarker Thymus and Activation-Regulated Chemokine (TARC) in babies increases their chances of developing atopic dermatitis.

Plaque Psoriasis Treatment: Roflumilast Phase III Results

Experts in plaque psoriasis discuss the primary endpoint data responses of roflumilast in the DERMIS-1/DERMIS-2 trials.

Roflumilast Itch Response for Plaque Psoriasis Treatment

Linda Stein Gold, MD, discusses the itch response of roflumilast for the treatment for plaque psoriasis.

Top Meeting Takeaways From the Fall Clinical Conference

Clinicians fresh from the Fall Clinical Dermatology Conference discuss their top meeting takeaways and share some recommendations.

Frontline Forum Part 5: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

In part 5 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.